Skip to main content

Prostate Cancer Clinical Trials

Review the prostate cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 201-225 of 520

Testosterone and ZEN-3694 followed by Enzalutamide and ZEN-3694 for the Treatment of Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, The COSMYC Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Eflornithine and Testosterone Followed by Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, APEX Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 2 locations
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide with Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
177Lu-PSMA-617 for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with Bone Marrow Involvement and Cytopenia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pembrolizumab with 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
XL092 for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, PRO-XL Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
An Investigational Scan (HP 13C MRI) for Assessing Response to Treatment with Abiraterone Acetate and Prednisone prior to Surgery in Patients with High-Risk Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
Ivonescimab for the Treatment of Patients with Locally Advanced, Unresectable and/or Metastatic Cutaneous Squamous Cell Cancer and Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
High Dose Rate Brachytherapy in Treating Patients with Prostate Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
High-Dose Rate Brachytherapy Boost with Stereotactic Radiation Body Therapy to the Prostate and Pelvic Lymph Nodes for the Treatment of Unfavorable Intermediate or Higher Risk Prostate Cancer
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Abemaciclib before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 2 locations
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Status: Active
Location: 3 locations
Cell Therapy (STEAP1 CART) with Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Stereotactic Body Radiation Therapy and 177Lu-PSMA-617 for the Treatment of Locally Advanced Prostate Cancer, STARLiT Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
REGN5678 before Surgery for Treating Patients with High-Risk Localized Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas